Uthorization Of Sotrovimab For Injection For Use In Relation To The Covid-19 Pandemic

Sotrovimab for Injection Recall Summary Sotrovimab for Injection has been authorized for use in Canada to treat COVID-19. This authorization relates to product safety concerns associated with the COVID-19 pandemic. The product is distributed across Canada.

Reason

COVID - Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2021-10-04

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/8c3c31ce-1e85-479f-810b-ea1db8e010ef